In this current investigation, we showed that treatment of mice with a CCK-BR antagonist, proglumide, could inhibit RIL-175 tumor growth, implying that this drug is blocking the actions of endogenous CCK or gastrin at the receptor. The gene discussed is CCKBR; the disease is neoplasm.